Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

News

July 22, 2024
PRESS RELEASE: On July 10, 2024, a new research paper was published in Oncotarget, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.” continue reading »

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

News

July 19, 2024
PRESS RELEASE: On July 2, 2024, a new editorial was published in Oncotarget, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.” continue reading »

Using Early On-treatment Circulating Tumor DNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer

News

July 17, 2024
PRESS RELEASE: On July 2, 2024, a new editorial was published in Oncotarget, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.” continue reading »

HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity

News

July 16, 2024
PRESS RELEASE: On June 20, 2024, a new editorial was published in Oncotarget, entitled, “HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity.” continue reading »

Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Malignant Pleural Mesothelioma

Oncotarget

July 15, 2024
PRESS RELEASE: On June 20, 2024, a new research paper was published in Oncotarget, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.” continue reading »